HeLa Genome Data Access Working Group

Report to the Advisory Committee to the Director

September 5, 2014

Renee Jenkins, MD

Professor and Chair Emeritus, Department of Pediatrics and Child Health Howard University

Presentation Overview

- Background on the HeLa Genome Data Access Working Group
 - Revisions to the Special Instructions for Preparing a Research Use Statement for Requesting Access to HeLa Cell Genome Sequence Data in dbGaP
- HeLa Genome Data Access Requests
- Workshop on Scientific and Ethical Issues Related to Open-Access HeLa Genomic Data
- ACD Discussion, Vote, and Recommendations

The HeLa Genome Data Use Agreement

Per the agreement between NIH and the Lacks family, NIH requests that *all researchers*:

- Apply for access to HeLa whole genome sequence in the database of Genotype and Phenotype (dbGaP)
- Abide by terms outlined in the HeLa Genome Data Use Agreement, such as:
 - Data can only be used for biomedical research only; this does not include the study of population origins or ancestry
 - Requestors are not to make contact with the Lacks family
 - Requestors are to disclose any commercial plans
 - Requestors are to include an acknowledgment in publications and presentations
- Deposit future whole genome sequence data into dbGaP

Role of HeLa Genome Data Access Working Group

- Evaluate requests to access HeLa cell genome data in dbGaP for consistency with the terms of the HeLa Genome Data Use Agreement
- Report findings to the Advisory Committee to the Director
- Make recommendations to the ACD on changes to the terms specified in the HeLa Genome Data Use Agreement

HeLa Genome Data Access Working Group Roster

Renee Jenkins, M.D. (Chair)

Professor and Chair Emeritus Department of Pediatrics and Child Health Howard University

Russ B. Altman, M.D., Ph.D.

Professor, Bioengineering, Genetics, & Medicine Director, Biomedical Informatics Training Program Stanford University

Ruth Faden, Ph.D., M.P.H.

Philip Franklin Wagley Professor in Biomedical Ethics Director, Johns Hopkins Berman Institute of Bioethics Johns Hopkins University

Kathy Hudson, Ph.D.

Deputy Director for Science, Outreach, and Policy National Institutes of Health

David Lacks Jr. Representative, Henrietta Lacks Family Baltimore, MD

Richard M. Myers, Ph.D.

President, Director and Faculty Investigator HudsonAlpha Institute

Robert Nussbaum, M.D.

Professor of Medicine Chief of Division of Genomic Medicine University of California, San Francisco

Veronica Spencer

Representative, Henrietta Lacks Family Baltimore, MD

Clyde W. Yancy, M.D.

Professor in Medicine-Cardiology and Medical Social Sciences Chief, Division of Medicine-Cardiology Northwestern University Feinberg School of Medicine



5

Working Group Evaluation Criteria

- Is the proposed research focused on health, medical, or biomedical research objectives?
 - Is the proposed research related to determining the ancestry or population origins of HeLa cells?
- Are there any plans to develop intellectual property? Specifically:
 - Does the requestor anticipate or foresee IP or developing commercial products or services from the proposed research?
 - Has the requestor agreed to notify NIH if their plans for IP or commercial products change?
- Are there any plans to publish or present findings?

Revision to the "Special Instructions"

- A non-technical summary (lay language summary) of the proposed research is to be included in each data access request
 - The non-technical summaries provided by many of the requestors have been inadequate, and the Working Group relies on them to understand the request.
- Because of this, the Working Group has developed clarifying language in the "Special Instructions" regarding expectations for the Non-Technical Summary:

"In addition to the Research Use Statement, a requestor is required to also provide a **Non-Technical Research Summary**. The non-technical summary should describe the purpose and objectives of the proposed research in terms that are understandable to a lay reader. In addition to informing the HeLa Genome Data Access Working Group, which is composed of a multi-disciplinary scientific and clinical experts as well as members of the public, the non-technical summary is posted on the public portion of the dbGaP HeLa Cell Genome Sequencing Studies webpage."

Types of Findings Reported by the Working Group

In evaluating a Data Access Request, the Working Group will report a finding as:

- **Consistent** with the Data Use Agreement
- **Inconsistent** with the Data Use Agreement
- Conditional (will be consistent with the Data Use Agreement if NIH staff find that additional information obtained from the Requestor is satisfactory)
- Pending (will require a re-evaluation from the Working group once additional information is obtained from the Requestor)

HeLa Data Access Requests

9

Update on HeLa Data Access Requests

 30 Data Access Requests evaluated by the Working Group

Number of	Status	
Requests		
21	Approved by NIH Director	
1	Disapproved by NIH Director	
4	Pending (require re-evaluation by the Working Group)	
4	Being reported today	

• 10 approved requestors have downloaded the data

Working Group Findings: Evaluation of Access Requests

Since the last ACD meeting, the Working Group has found four Data Access Requests consistent with the HeLa Data Use Agreement

Project Title	Requestor's Affiliation	Project Overview	Working Group Findings: Consistent with Data Use Agreement?
Analysis of Gene Expression, Splicing Regulation, and mRNA Degradation in Human Cells	University of California Berkeley	 The requestor plans to evaluate the effects of variations in the HeLa genome with that seen in other human cell lines, in order to learn more about gene regulation, structure and function. 	Yes
Development of Methods to Infer the 3D Structure of the Genome	University of Washington	 The overall goal of the project is to use the HeLa genome dataset to test hypotheses about three- dimensional folding of chromosomes, which is important for cellular function. 	Yes
Searching for Infectious Cancer Agents	University of Pittsburgh	The requestor would like to search the genomic sequence of various tumors to potentially discover new types of viral infections that cause cancer.	Yes
Polymorphisms in the shifted self peptidome following viral infection	Vanderbilt University; University of Texas, El Paso	 The requestor plans to study how the set of proteins found on the surface of cells change after a viral infection and how these vary among the population. 	Yes

Workshop on Scientific and Ethical Issues Related to Open-Access HeLa Genomic Data

Background

- The current HeLa policy applies to whole genome data only
- Other HeLa genomic data types are currently in openaccess and include, for example, epigenetic or RNAseq data
- Need to evaluate whether the Policy should apply prospectively to other HeLa genome data types
- Workshop on Scientific And Ethical Issues Related to Open-Access HeLa Genomic Data was held on May 14

Workshop Participants

Russ B. Altman, M.D., Ph.D. Stanford University

Dixie B. Baker, Ph.D. Genetic Alliance

Barbara Bowles Biesecker, Ph.D., MS, CGC National Institutes of Health

Vence L. Bonham, J.D. National Institutes of Health

Lawrence C. Brody, Ph.D. National Institutes of Health

John D. Carpten, Ph.D. Translational Genomics Research Institute

Stephen J. Chanock, M.D. National Institutes of Health

Giselle Corbie-Smith, M.D., M.Sc. University of North Carolina School of Medicine

Yaniv Erlich, Ph.D. Whitehead Institute

Ruth R. Faden, Ph.D., M.P.H. Johns Hopkins University

Paul Flicek, Ph.D. European Bioinformatics Institute

Nanibaa' Garrison, Ph.D. Vanderbilt University

Aaron Goldenberg, Ph.D., M.P.H. Case Western Reserve University Laurie Goodman, Ph.D. GigaScience

Hank Greely, J.D. Stanford University

Eric Green, M.D., Ph.D. National Institutes of Health

Kathy L. Hudson, Ph.D. National Institutes of Health

Chanita Hughes-Halbert, Ph.D. Medical University of South Carolina

Renee R. Jenkins, M.D. Howard University

Lynn B. Jorde, Ph.D. University of Utah

Rick Kittles, Ph.D. University of Illinois at Chicago

David Lacks, Jr. Representative, Henrietta Lacks Family

Kimberley Lacks Representative, Henrietta Lacks

Shirley Lacks Representative, Henrietta Lacks

Sandra Soo-Jin Lee, Ph.D. Stanford School of Medicine

Daniel MacArthur, Ph.D. Broad Institute of MIT and Harvard **Pilar Ossorio, J.D., Ph.D.** University of Wisconsin

Jim Ostell, Ph.D. National Institutes of Health

Laura Lyman Rodriguez, Ph.D. National Institutes of Health

Charles Rotimi, Ph.D. National Institutes of Health

Charmaine D. M. Royal, Ph.D. Duke University

Jay Shendure, M.D., Ph.D. University of Washington

Veronica Spencer Representative, Henrietta Lacks Family

Lars Steinmetz, Ph.D. European Molecular Biology Laboratory

Susan M. Wolf, J.D. University of Minnesota

Clyde W. Yancy, M.D. Northwestern University Feinberg School of Medicine

Ma'n Zawati, LL.B., LL.M. McGill University

Workshop Agenda Overview

- HeLa genomic data currently in open access and future considerations
- Scientific value of HeLa genomic data
- The information revealed by and the privacy risks of different types of open-access HeLa genomic data
- Ethical implications of open versus controlled data access
- Applying the NIH HeLa Genomic Data Policy to other HeLa genomic data types

Preferences of Participating Lacks Family Members

- Desire that scientists have efficient and effective access to HeLa genomic data
- Concerned about delaying or halting the progress of science with HeLa cells
- Want to be informed about scientific developments with the use of HeLa cells

Preliminary Workshop Outcomes

- HeLa Genome Data Use Agreement
 - Not much enthusiasm for expanding policy
- Open vs Controlled Access to HeLa Genomic Data
 - HeLa genomic data, beyond whole genome sequences, do not need to be kept in controlled access
- HeLa Cell Research Collection
- HeLa Cell Research Symposia
- Information sharing with the Lacks family
 - Periodic summary of how HeLa cells and sequences are being used in research

Working Group Findings

- Privacy considerations are not significant enough to outweigh the scientific and public health benefits of maintaining the other types of genomic data in unrestricted databases and, as such, the NIH HeLa genome data policy need not change.
- A periodic symposium in association with an extant national scientific meeting (e.g., AAAS, ASCB, ASHG) would be the most useful, comprehensive, and feasible approach to capture and disseminate information on HeLa cell research.

Next Steps

- ACD to make a recommendation to the NIH Director
- NIH to consult with the Lacks family
- NIH Director will make a final decision on how to move forward

ACD Discussion, Vote, and Recommendations

Working Group Findings on Four Data Access Requests

Project Title	Requestor's Affiliation	Project Overview	Working Group Findings: Consistent with Data Use Agreement?
Analysis of Gene Expression, Splicing Regulation, and mRNA Degradation in Human Cells	University of California Berkeley	 The requestor plans to evaluate the effects of variations in the HeLa genome with that seen in other human cell lines, in order to learn more about gene regulation, structure and function. 	Yes
Development of Methods to Infer the 3D Structure of the Genome	University of Washington	• The overall goal of the project is to use the HeLa genome dataset to test hypotheses about three- dimensional folding of chromosomes, which is important for cellular function.	Yes
Searching for Infectious Cancer Agents	University of Pittsburgh	The requestor would like to search the genomic sequence of various tumors to potentially discover new types of viral infections that cause cancer.	Yes
Polymorphisms in the shifted self peptidome following viral infection	Vanderbilt University; University of Texas, El Paso	 The requestor plans to study how the set of proteins found on the surface of cells change after a viral infection and how these vary among the population. 	Yes

Working Group Findings on the Workshop

- No change to the NIH HeLa genome data policy.
- NIH should hold a periodic, special session at a national scientific meeting (e.g., AAAS, ASCB, ASHG) that would focus on revolutionary research utilizing HeLa cells.